Stiefel, a GSK Company
GSK is a focused biopharma company dedicated to uniting science, technology, and talent to get ahead of disease. Their mission is to positively impact the health of 2.5 billion people by the end of the decade through innovative research, development, and global partnerships. They focus on four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. GSK emphasizes responsible access to medicines, global health security, environmental sustainability, inclusion, ethical standards, and product governance. They are committed to creating a culture of innovation, inclusion, and responsible business practices, aiming to deliver sustainable health impact at scale.
Industries
Nr. of Employees
Very Large (1000+)
Stiefel, a GSK Company
Products
Vaccines portfolio
A portfolio of vaccines targeting infectious diseases across age groups, supported by R&D, large-scale manufacturing and global distribution.
Specialty medicines portfolio
A range of specialty medicines addressing oncology, HIV, respiratory and immune-mediated diseases developed using precision-medicine approaches and biomarker stratification.
General medicines portfolio
Medicines for primary care and community settings including respiratory therapies and anti-infectives used in standard clinical practice.
Vaccines portfolio
A portfolio of vaccines targeting infectious diseases across age groups, supported by R&D, large-scale manufacturing and global distribution.
Specialty medicines portfolio
A range of specialty medicines addressing oncology, HIV, respiratory and immune-mediated diseases developed using precision-medicine approaches and biomarker stratification.
General medicines portfolio
Medicines for primary care and community settings including respiratory therapies and anti-infectives used in standard clinical practice.
Services
Design and conduct of clinical studies combining patient-derived ex vivo models, computational predictions, machine learning and imaging to evaluate predictive biomarkers and treatment strategies.
Collaborative discovery programmes combining large-scale genetic datasets, genomics analysis and AI/ML to identify and de-risk therapeutic targets for development.
Manufacture and global distribution services for vaccines and biologics with GMP processes to support high-volume production, quality assurance and regulatory compliance.
Programmes to improve affordability and availability of health technologies through licensing, technology transfer, capacity building and local manufacture enablement.
Systems and processes to publish clinical study information, maintain public study registries and provide regulated disclosure to support reproducibility and secondary research.
Development and implementation of third-party oversight frameworks, supplier audits and compliance programmes to manage risks across partnerships and supply chains.
Design and conduct of clinical studies combining patient-derived ex vivo models, computational predictions, machine learning and imaging to evaluate predictive biomarkers and treatment strategies.
Collaborative discovery programmes combining large-scale genetic datasets, genomics analysis and AI/ML to identify and de-risk therapeutic targets for development.
Manufacture and global distribution services for vaccines and biologics with GMP processes to support high-volume production, quality assurance and regulatory compliance.
Programmes to improve affordability and availability of health technologies through licensing, technology transfer, capacity building and local manufacture enablement.
Systems and processes to publish clinical study information, maintain public study registries and provide regulated disclosure to support reproducibility and secondary research.
Development and implementation of third-party oversight frameworks, supplier audits and compliance programmes to manage risks across partnerships and supply chains.
Expertise Areas
- Translational oncology and organoid modelling
- Digital biological twins and computational disease modelling
- AI/ML-driven predictive analytics and multi-modal data integration
- Human genetics and population-scale genomics
Key Technologies
- Organoid culture and patient-derived ex vivo models
- Digital biological twin modelling
- Artificial intelligence and machine learning
- Next-generation sequencing and genomic analysis
News & Updates
GSK announced its first quarter 2025 results on Wednesday 30 April.
Scientists at GSK are using digital biological twins and organoids to create personalized solutions for cancer patients, including a trial mapping lung cancer tumors for NHS patients.
GSK scientists are using organoids and digital twins to develop personalized cancer treatments, aiming to improve patient outcomes.
GSK announced its first quarter 2025 results on Wednesday 30 April.
Scientists at GSK are using digital biological twins and organoids to create personalized solutions for cancer patients, including a trial mapping lung cancer tumors for NHS patients.
GSK scientists are using organoids and digital twins to develop personalized cancer treatments, aiming to improve patient outcomes.